Real-World Evaluation of Disparities in Prostate Cancer Outcomes - Daniel Spratt

May 31, 2019

Daniel Spratt and Todd Morgan discuss the analysis of why is it that black men appear to be dying more often of prostate cancer.  They review their approach to understanding more about this real-world question.


Todd Matthew Morgan MD Associate Professor Specialties: Urology Area of Practice: Prostate Cancer, including robotic prostatectomy and active surveillance; Bladder Cancer, including bladder preservation approaches as well as open and robotic radical cystectomy; Kidney Cancer, including open and robotic approaches, and nephron-sparing (i.e. partial nephrectomy) when appropriate; and Penile Cancer, including robotic inguinal lymphadenectomy. Michigan Medicine Urology Oncology Clinic | Rogel Cancer Center

Daniel Spratt, MD, Tenured Full Professor of Radiation Oncology and a leader in Prostate and Spine malignancies. Chief of the Genitourinary Radiotherapy Program, Associate Chair of Clinical Research, and the Laurie Snow Endowed Research Professor in the Department of Radiation Oncology. Co-Chair of the Genitourinary Clinical Research Team and co-Director of the Spine Oncology Program, in the Rogel Cancer Center, The University of Michigan, Ann Arbor, Michigan.

Charles J. Ryan, MD, B.J. Kennedy Chair in Clinical Medical Oncology at the University of Minnesota and Director of the Division of Hematology, Oncology, and Transplantation. He previously held the position of Professor of Clinical Medicine and Urology and the Clinical Program Leader for Genitourinary Medical Oncology at the UCSF Helen Diller Family Comprehensive Cancer Center